U-CyTech Overview
- Founded
-
1999
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
U-CyTech General Information
Description
Developer of biomedical products designed to offer immunoassays for human, monkey, and rodent use. The company's products include cytokine enzyme-linked immunosorbent assays, T and B cell assays, and enzyme-linked Immuno spot systems which are designed for the ex vivo detection of individual protein-secreting cells, enabling clients to prepare efficient medicines for their biological research.
Contact Information
Website
www.ucytech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Yalelaan 48
- 3584 CM Utrecht
- Netherlands
+31 085 000 0000
U-CyTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jan-1999 | Completed | Generating Revenue |
U-CyTech Patents
U-CyTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1372702-B1 | Treatment of hypoxia/ischaemia related blood flow resistance using beta-interferon | Inactive | 03-Apr-2001 | 0000000000 | |
| US-20040136957-A1 | Administering a therapeutically relevant dose of ifn (interferon) type-i or a functional part, derivative and/or analogue thereof | Inactive | 03-Apr-2001 | 0000000000 | |
| US-20040105843-A1 | Prevention of cellular damage in disease resulting from h/i-related blood flow resistance due to occlusion of blood vessels | Inactive | 03-Apr-2001 | 0000000000 | |
| AU-2002249692-A1 | Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation | Inactive | 03-Apr-2001 | 0000000000 | |
| DE-60129472-D1 | Treatment of hypoxya / ischaemia blood flow resistance with beta-interferon | Inactive | 03-Apr-2001 | A61K38/212 |
U-CyTech Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Peter Van der Meide Ph.D | Founder, Owner & Co-Chief Executive Officer | ||
| Nicole Besouw Ph.D | Co-Chief Executive Officer |
U-CyTech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
U-CyTech Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Utrecht Holdings | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 |